Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Galantamine for Alzheimer's disease

Esta versión no es la más reciente

ver la versión actual 25 enero 2006

Información

DOI:
https://doi.org/10.1002/14651858.CD001747.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 18 octubre 2004see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Demencia y trastornos cognitivos

Copyright:
  1. Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Clement Loy

    Correspondencia a: Level 7, Garvan Institute of Medical Research, Darlinghurst, Australia

    [email protected]

  • Lon Schneider

    University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA

Contributions of authors

Clement Loy took over from Jason Olin as main reviewer for the update of the review in November 2003. He dealt with article collection, in‐ and exclusion of new references, updated the data‐ analyses and rewrote the manuscript where necessary

Lon Schneider co‐wrote, reviewed article coding, and assisted with editing the manuscript, for the original review as well as all subsequent updates.

Consumer Editors: Enid Light and Mervyn Richardson

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • National Institute of Mental Health (MH01368 (OLIN), MH19074, MH48759), USA.

  • National Institute on Aging (AG05142), USA.

  • NIMH Clinical Antipsychotic Trials of Interventions Effectiveness, USA.

Declarations of interest

Dr. Schneider and the University of Southern California have received clinical trials‐and other contracts from Janssen Pharmaceutica and Johnson and Johnson, Inc. Dr. Schneider has served as a consultant to Janssen, Pfizer, and Novartis, all manufacturers of cholinesterase inhibitors used to treat AD, and to Forest Pharmaceuticals, manufacturer of memantine used to treat AD, for which he received payments. Dr. Loy has received a Wellcome Trust Travelling Award in relation to his work with the Cochrane Collaboration.

Acknowledgements

We gratefully acknowledge the contributions of Jason Olin who was the original main reviewer of this review and of Enid Light, the consumer editor.

Version history

Published

Title

Stage

Authors

Version

2006 Jan 25

Galantamine for Alzheimer's disease and mild cognitive impairment

Review

Clement Loy, Lon Schneider

https://doi.org/10.1002/14651858.CD001747.pub3

2004 Oct 18

Galantamine for Alzheimer's disease

Review

Clement Loy, Lon Schneider

https://doi.org/10.1002/14651858.CD001747.pub2

2002 Jul 22

Galantamine for Alzheimer's disease

Review

Jason T Olin, Lon Schneider

https://doi.org/10.1002/14651858.CD001747

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.